Mindfulness training shifted prefrontal cue responses in opioid use disorder

Design

Randomised clinical trial with fMRI outcomes

Population

59 inpatients with opioid use disorder in New York

Primary outcome

Change in fMRI response to drug and natural reward cues

Effect

Reduced drug-biased frontal activity; longer abstinence at about 4 months (Cohen w 0.19)

Mindfulness-Oriented Recovery Enhancement (MORE) combines mindfulness, reappraisal of drug cues and attention to natural rewards. This trial randomised inpatients with opioid use disorder at a New York rehabilitation unit to eight weekly group sessions of MORE or supportive psychoeducation. The primary outcome was brain response on functional MRI.

In 59 participants, MORE reduced drug-biased activity in frontal regions when patients were asked to damp down drug cues and attend to natural rewards. In the MORE group, that shift was associated with lower cue-induced craving. In a follow-up subset of 38, abstinence at about four months was longer with MORE (Cohen w 0.19).

This is a small mechanistic trial. The abstinence result is a secondary outcome in a subset, with a small effect size, and the brain findings are surrogate measures.

The clinical reading is modest: a structured mindfulness programme is a plausible adjunct to medication for opioid use disorder, not a substitute for it.

• MORE is an eight-session group programme of mindfulness, cue reappraisal and savouring natural rewards.
• Brain responses to drug cues shifted in the MORE group, and craving fell in step.
• Abstinence at about four months was longer with MORE, but in only 38 patients.
• Keep opioid agonist treatment as the foundation; consider psychological adjuncts alongside it.
• Ask patients about cue-triggered craving, which this approach targets.

Why it matters

It gives a mechanism for why a psychological adjunct might reduce craving, which strengthens the case for testing it in larger trials.

Don't overread it

The abstinence result is a secondary outcome in a small subset, so it does not show clinical benefit on its own.

The statistics, in plain English

Cohen's w of 0.19 is a small effect. The imaging changes are statistically robust but are surrogate markers; they show the brain responded differently, not that patients did better in the long run.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.